- Home
- EMPD vs COYA Comparison
EMPD vs COYA Comparison
Compare EMPD & COYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | EMPD | COYA |
|---|---|---|
| Founded | 2020 | 2020 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 88.4M | 102.7M |
| IPO Year | 2021 | 2022 |
Fundamental Metrics
Financial Performance| Metric | EMPD | COYA |
|---|---|---|
| Price | $2.20 | $3.24 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $15.21 |
| AVG Volume (30 Days) | ★ 180.3K | 166.4K |
| Earning Date | 11-06-2026 | 11-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 94.47 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $974,977.00 | ★ $7,945,753.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $335.89 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 123.57 |
| 52 Week Low | $1.91 | $2.72 |
| 52 Week High | $5.84 | $6.62 |
Technical Indicators
Market Signals| Indicator | EMPD | COYA |
|---|---|---|
| Relative Strength Index (RSI) | 36.67 | 36.25 |
| Support Level | N/A | N/A |
| Resistance Level | $3.23 | $5.17 |
| Average True Range (ATR) | 0.24 | 0.35 |
| MACD | -0.06 | -0.03 |
| Stochastic Oscillator | 25.89 | 32.91 |
Price Performance
Historical ComparisonAbout EMPD Empery Digital Inc.
Empery Digital Inc is an all-electric, off-road powersports vehicle company developing and building electric two and four-wheel motorcycles and utility terrain vehicles, also known as side-by-sides, along with a complete line of upgrades and accessories. The company's products include motorcycle and UTV products that are all-electric and designed for off-road use.
About COYA Coya Therapeutics Inc.
Coya Therapeutics Inc is a clinical-stage biotechnology company focused on developing proprietary new therapies to enhance the function of regulatory T cells (Tregs). The company's initial development programs are focused on neurodegenerative, chronic inflammatory, autoimmune, and metabolic diseases with high unmet medical needs.